Palisade Bio Inc
PALI
Company Profile
Business description
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Contact
4600 South Syracuse Street
Suite 900
DenverCO80237
USAT: +1 858 704-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14
Stocks News & Analysis
stocks
This ASX supermarkets business is now underperforming its largest competitor
Competition restrains long-term margins.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.40 | 8.30 | 0.09% |
| CAC 40 | 7,976.12 | 138.72 | -1.71% |
| DAX 40 | 23,991.27 | 301.11 | -1.24% |
| Dow JONES (US) | 48,941.90 | 557.37 | -1.13% |
| FTSE 100 | 10,363.93 | 14.89 | -0.14% |
| HKSE | 26,095.88 | 319.35 | 1.24% |
| NASDAQ | 25,067.80 | 46.64 | -0.19% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 12,997.41 | 100.27 | -0.77% |
| S&P 500 | 7,200.75 | 29.37 | -0.41% |
| S&P/ASX 200 | 8,652.40 | 10.70 | 0.12% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |